Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01531803 · ClinicalTrials.gov registry record · Phase 4

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

A Phase 4 study, sponsored by Kedrion S.p.A..

Terminated
Registry status
Phase 4
Development phase
3
Enrollment target

NCT01531803 is a Phase 4 study that was terminated before completion, run by Kedrion S.p.A.. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01531803, a Phase 4 study, was terminated before completion, sponsored by Kedrion S.p.A..

TERMINATED
Registry status
Phase 4
Development phase
3 participants
Enrollment target

Study Summary

This is a randomized, controlled, open-label clinical trial aimed to evaluate the Safety of Kedbumin 25% Compared to Normal Saline Solution in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients Undergoing Major Elective Surgery. It will be conducted at approximately 5 surgical and pediatric intensive care units (SICU/NICU/PICU) in the US, over a period of 19 months, and the study population will consist of at least 60 male and female pediatric subjects between 0 days and 12 years of age, undergoing cardiac, abdominal, orthopedic or transplant surgery with an approximately equal number of subjects (n=10 to 25) in three of the four age groups: (29 days to 23 months), (2 to 5 years 11 months) and (6 years to 12 years) cohorts.

Interventions

  • DRUG Normal Saline Solution
  • DRUG Kedbumin 25%

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2015-02-05
Est. Completion 2015-07-15
Phase Phase 4

Sponsor

Kedrion S.p.A.

8 total trials

What the Registry Record Tells You About NCT01531803

The ClinicalTrials.gov registry entry for NCT01531803 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kedrion S.p.A., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Normal Saline Solution is the first listed.

NCT01531803 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01531803 about?

NCT01531803 is a clinical study titled "Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients". This is a randomized, controlled, open-label clinical trial aimed to evaluate the Safety of Kedbumin 25% Compared to Normal Saline Solution in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients Undergoing Major Elective Surgery. It will be conducted at approximately 5 surgical and pedi...

What is the current status of trial NCT01531803?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2015-02-05. Estimated completion is 2015-07-15.

What interventions are being tested in trial NCT01531803?

The interventions under investigation include: Normal Saline Solution (DRUG), Kedbumin 25% (DRUG).

Who is sponsoring clinical trial NCT01531803?

This trial is sponsored by Kedrion S.p.A., which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.